5,000 patients join Long-Term study to unlock mysteries of rare blood cancers

NCT ID NCT07362225

First seen Jan 28, 2026 · Last updated Jun 05, 2026 · Updated 20 times

Summary

This study is a long-term observation of 5,000 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, insurance data, and patient surveys over at least five years to track symptoms, treatments, and how the disease changes. No new treatments are tested—the goal is to learn from real-world experiences to improve future care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MPN Research Foundation

    RECRUITING

    Chicago, Illinois, 60654, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera blast phase chronic myelogenous leukemia, BCR-ABL1 positive bone marrow neoplasm Disease Progression essential thrombocythemia hematopoietic and lymphoid system neoplasm leukemia, myeloid, accelerated-phase myelodysplastic/myeloproliferative neoplasm Myeloproliferative Disorders myeloproliferative neoplasm primary myelofibrosis Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACCELERATED PHASE MPN ACCELERATED PHASE MPN ACCELERATED PHASE MYELOPROLIFERATIVE NEOPLASM ACCELERATED PHASE MYELOPROLIFERATIVE NEOPLASM AGNOGENIC MYELOID METAPLASIA BLAST PHASE MPN BLAST PHASE MPN BLAST PHASE MYELOPROLIFERATIVE NEOPLASM BLAST PHASE MYELOPROLIFERATIVE NEOPLASM CHRONIC IDIOPATHIC MYELOFIBROSIS ESSENTIAL THROMBOCYTHEMIA (ET) ET (ESSENTIAL THROMBOCYTHEMIA) IDIOPATHIC MYELOFIBROSIS MDS/MPN CROSSOVER SYNDROMES MF MPN MPN (MYELOPROLIFERATIVE NEOPLASMS) MPN-ASSOCIATED MYELOFIBROSIS MYELOFIBROSIS MYELOFIBROSIS (MF) MYELOFIBROSIS (PMF) MYELOFIBROSIS DUE TO AND FOLLOWING POLYCYTHEMIA VERA MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH HIGH MOLECULAR RISK MUTATIONS MYELOFIBROSIS, POST ET MYELOFIBROSIS, POST PV MYELOFIBROSIS, PRIMARY MYELOFIBROSIS; PRIMARY MYELOFIBROSIS; POST-POLYCYTHEMIA VERA MYELOFIBROSIS; POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS MYELOPROLIFERATIVE DISORDER MYELOPROLIFERATIVE DISORDERS MYELOPROLIFERATIVE DISORDERS (MPD) MYELOPROLIFERATIVE NEOPLASM WITH 10% BLASTS OR HIGHER MYELOPROLIFERATIVE NEOPLASM WITH 10% BLASTS OR HIGHER MYELOPROLIFERATIVE NEOPLASM(MPN)-ASSOCIATED MYELOFIBROSIS MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASMS MYELOPROLIFERATIVE NEOPLASMS MYELOPROLIFERATIVE NEOPLASMS (MPNS) MYELOPROLIFERATIVE NEOPLASMS (MPNS) POLYCYTHEMIA VERA POLYCYTHEMIA VERA (PV) POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS POST POLYCYTHEMIA VERA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-ET MF) POST-ET MF POST-POLYCYTHEMIA VERA MYELOFIBROSIS POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF) POST-PV MF POST-PV MF PRE-FIBROTIC MYELOFIBROSIS PRIMARY MYELOFIBROSIS (MF) PRIMARY MYELOFIBROSIS (PMF) SECONDARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS (POST-POLYCYTHEMIA VERA MYELOFIBROSIS, POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS) SECONDARY MYELOFIBROSIS IN MYELOPROLIFERATIVE DISEASE THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) THROMBOCYTHEMIA, ESSENTIAL THROMBOCYTHEMIA, HEMORRHAGIC